Luminex acquires EraGen Biosciences

Luminex Corporation (NASDAQ: LMNX) today announced the completion of its acquisition of privately-held EraGen Biosciences, Inc., an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications, for $34 million in cash.

Luminex expects the EraGen acquisition will add between $5 million and $7 million to 2011 consolidated revenue. On a GAAP basis, inclusive of purchase related costs, Luminex expects this acquisition to be dilutive in 2011 and accretive to earnings in 2012.  Luminex expects the acquisition to be neutral to earnings in 2011 on a non-GAAP basis as a result of acquisition costs and required accounting adjustments. These costs are not expected to repeat in subsequent periods.


Luminex Corporation


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Luminex. (2019, June 20). Luminex acquires EraGen Biosciences. News-Medical. Retrieved on November 28, 2022 from

  • MLA

    Luminex. "Luminex acquires EraGen Biosciences". News-Medical. 28 November 2022. <>.

  • Chicago

    Luminex. "Luminex acquires EraGen Biosciences". News-Medical. (accessed November 28, 2022).

  • Harvard

    Luminex. 2019. Luminex acquires EraGen Biosciences. News-Medical, viewed 28 November 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Luminex third quarter revenue increases 10% to $50.0 million